| 【英語論文】 |
| |
原著論文 |
| |
|
1. Watanabe J, Ito Y,Saeki T,Masuda N,Takano T,Takao S,Nakagami K,Tsugawa K,Nakagawa S,Kanatani K,Nakayama T. Safety evaluation of trastuzumab emtansine in Japanese patients with HER2-positive advanced breast cancer.in vivo. 2017;31:493-500. |
| |
|
2. Watanabe J, Hayashi T,Tadokoro Y,Nishimura S,Takahashi K. Clinical pattern of primary systemic therapy and outcomes of estrogen receptor-positive, HER2-negative metastatic breast cancer: a review of a single institution.Breast Cancer Res Treat. 2017;166:911-7. |
| |
|
3. Watanabe J, Ito Y, Ohsumi S, Mizutani M, Tashiro H, Sakurai K, Takahashi M, Saito T, Tsurutani J, Mukai H, Yoshinami T, Takao S, Yamamoto Y, Matsuoka T, Iwase H, Iwata H, Nakamura S, Saeki T. Safety and effectiveness of eribulin in Japanese patients with locally advanced or metastatic breast cancer:a post-marketing observational study.Invest New Drugs. 2017;35:791-9. |
| |
|
4.Matsuo S, Watanabe J , Mitsuya K, Hayashi N, Nakasu Y, Hayashi M. Brain metastasis in patients with metastatic breast cancer in the real world: a single-institution, retrospective review of 12-year follow-up.Breast Cancer Res Treat. 2017;162:169-79. |
